Novo Nordisk Expands Thai Semaglutide Offering While Danish Regulator Logs Fourth 2026 Breach

Novo Nordisk launched a higher-dose semaglutide for type 2 diabetes in Thailand, as Denmark's regulator cites a fourth 2026 violation and Q3 results loom Nov. 4.

Novo Nordisk rolled out a higher-dose version of its semaglutide treatment for adults with type 2 diabetes in Thailand on Wednesday, extending its metabolic portfolio deeper into Southeast Asia through subsidiary Novo Nordisk Pharma (Thailand) Ltd. The launch comes as the Danish drugmaker juggles pipeline expansion, a pending FDA review and mounting regulatory friction at home.

Investors will get their next hard read on the business on Nov. 4, 2026, at 07:30 CET, when the company reports results for the first three quarters of the year. The interim statement is expected to show how sales and earnings momentum are holding up across its established diabetes and obesity franchises.

Pipeline Bets and a $2.6 Billion Licensing Deal

Beyond marketing its current lineup, Novo Nordisk is pushing to broaden its development slate. An exclusive licensing agreement with Hengrui Pharma handed the company rights to the oral GLP-1/GIP candidate HRS-1596, covering development and commercialization outside mainland China, Hong Kong, Macau and Taiwan.

The financial scale of that partnership is substantial: the deal carries a potential total value of up to $2.6 billion, including a $300 million upfront payment plus milestone payments and royalties. The arrangement sharpens Novo Nordisk's strategic tilt toward tablet-based therapies.

Regulatory timelines elsewhere are proving less cooperative. For Denecimig, a candidate for hemophilia A, the FDA's review remains open while corrective measures at a manufacturing site are implemented. The agency did not flag deficiencies in the clinical efficacy or safety data. Novo Nordisk still targets a U.S. launch in the first half of 2027, subject to approval, and says the delay leaves its full-year financial guidance untouched.

Danish Watchdog Cites Fourth Violation of 2026

On the home front, Denmark's medicines regulator has accused Novo Nordisk of repeated legal breaches. Media reports indicate the company has violated statutory rules four times in 2026, three of them involving unlawful consumer-directed advertising for weight-loss drugs on LinkedIn. Danish law strictly prohibits direct-to-public promotion of prescription medicines.

The findings add to a string of regulatory rebukes in the company's home market. On Sept. 28, the Danish pharmaceutical industry's ethics committee fined Novo Nordisk 45,000 Danish kroner plus VAT over a joint Wegovy patient-support program run with service provider Falck, and ordered the arrangement discontinued in its then-current form. Novo Nordisk subsequently ended the Falck collaboration, according to media reports, while stressing it disagreed with the ethics council's decision.

Analysts Trim Targets as Shares Stay Deep in the Red

The regulatory headwinds land in an already demanding market environment. The stock closed at EUR 33.97 in the previous session, bringing its year-to-date decline to 23%. It remains well below its 52-week high of EUR 54.86, with the shares last changing hands at EUR 33.95.

Brokerages have been adjusting expectations in tandem. Danske Bank cut its price target to DKK 345 from DKK 365 on Wednesday while keeping a "Buy" rating. Deutsche Bank maintained its "Sell" stance and lowered its target to DKK 225 from DKK 245, after data presented at the EASD diabetes conference was judged subdued.

Even as the GLP-1 business expands globally, the Copenhagen reprimands underscore how tightly supervisors are policing the marketing of these in-demand medicines.